Strategic regional licensing partnership with Simcere Pharmaceutical Group to treat AD in Greater China US Phase 2 VIVA-MIND study for varoglutamstat in AD initiated as planned […]
Halle (Saale) / Munich, Germany, September 14, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of […]
Halle (Saale) / Munich, Germany, June 29, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biotechnology company focused on developing innovative small molecule-based […]
Halle (Saale) / Munich, Germany and Nanjing, China, June 29, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing […]
HALLE (SAALE) / MUNICH, GERMANY, June 28, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small […]
HALLE (SAALE) / MUNICH, GERMANY, June 25, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) today announced financial results and provided a corporate update for […]
HALLE (SAALE) / MUNICH, GERMANY, May 31, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that the publication of the 1st quarter 2021 […]
HALLE (SAALE) / MUNICH, GERMANY, May 17, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) invites all shareholders to Vivoryon’s annual general meeting of shareholders to […]
English conference call and webcast today, April 30th at 3:00 pm CEST (09:00 am EDT) a HALLE (SAALE) / MUNICH, GERMANY, April 30, 2021 – Vivoryon Therapeutics N.V. […]